Koji Matsumoto

13PUBLICATIONS
70CO-AUTHORS
Major global burdens of diseaseMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Ngā pūtaiao koiora-hauora, haumanu hoki o te Māori (Māori biomedical and clinical sciences)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Apr 21, 2026
Barriers and facilitators for online genetic care for hereditary cancer in Japan: findings from surveys of both clients and medical professionals.

|Mar 26, 2026
Sacituzumab govitecan in Japanese participants with HR+/HER2- metastatic breast cancer: primary results from the phase II ASCENT-J02 study.

Akihiko Shimomura, Takahiro Kogawa, Koji Matsumoto

|Jul 24, 2025
Current status of carboplatin desensitization therapy for gynecologic malignancies.

Hiroshi Nishio, Koji Matsumoto, Hiroaki Komatsu

|Sep 12, 2024
Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC.

Seock-Ah Im, Javier Cortes, David W Cescon

|Sep 11, 2024
Defining the clinical benefits of adding a neurokinin-1 receptor antagonist to control chemotherapy-induced nausea and vomiting in moderately emetogenic chemotherapy: a systematic review and meta-analysis of the clinical practice guidelines for antiemesis 2023 from the Japan society of clinical oncology.

Toshinobu Hayashi, Shun Yamamoto, Yoshiharu Miyata

|Aug 22, 2024
A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer.

Emi Noguchi, Takashi Yamanaka, Hirofumi Mukai

Pageof 3

Frequent Collaborators

3 joint publications

Kan Yonemori

2 joint publications

Yoichi Naito

2 joint publications

Shin Nishio

2 joint publications

Hiroaki Komatsu